A retrospective analysis evaluating toxicity of capecitabine/temozolomide in neuroendocrine tumours (NETs)
Latest Information Update: 20 Jun 2020
At a glance
- Drugs Capecitabine (Primary) ; Temozolomide (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions
Most Recent Events
- 20 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology